Protamine sulfate, a strong polycation, is used extensively in clinical medicine to block anticoagulant activity to heparin, a strong polyanion. Recent studies indicate that protamine may be a major cause of morbidity and mortality in patients who undergo cardiopulmonary bypass and that these reactions are not predictable in most cases. Furthermore, new low molecular weight heparins may not be as easy to neutralize as commercial heparin. Therefore, a new agent is urgently needed, to replace protamine, to block the anticoagulant activity of heparin without itself having anticoagulant or procoagulant activity or capacity to cause Type I hypersensitivity or to act on complement. One major mechanism by which polyions exert activity in vivo appears to be through the complement system. These studies will investigate a variety of polyions for capacity to regulate complement using state-of- the-art assays (Section D.2). Polyanions (polydisperse heparin and monodisperse heparin oligosaccharides) will be examined in detail to determine the structure and activity relationship for activity on complement (Section D.3). Polycations will be studied to determine specific mechanisms by which these basic substances regulate complement and again to determine the structure and activity relationship (Section D.4). The mechanism by which polycations preferentially inhibit the classical and polyanions preferentially inhibit the alternative pathways of complement will be determined (Section D.5). Affinity chromatography will be combined with conventional chromatography to purify heparin oligosaccharides with high capacity to bind complement (Section D.6). These heparin oligosaccharides will be studies for binding affinity to protamine, complement and a variety of polycations (Section D.7). These investigations will also determine the sequences in Hep which have high affinity for C3 and the sequence in C3 to which Hep binds. These studies should provide a more complete understanding of the complex role that polyions play in regulating complement activity and could lead to the development of new pharmacological agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI022350-06
Application #
3133321
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1985-09-30
Project End
1994-07-31
Budget Start
1992-08-01
Budget End
1994-07-31
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Caldwell, E E; Nadkarni, V D; Fromm, J R et al. (1996) Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int J Biochem Cell Biol 28:203-16
Booth, B A; Boes, M; Dake, B L et al. (1996) Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3. Growth Regul 6:206-13
Maves, K K; Guenthner, S T; Densen, P et al. (1995) Cloning and characterization of the cDNA encoding guinea-pig properdin: a comparison of properdin from three species. Immunology 86:475-9
Booth, B A; Boes, M; Andress, D L et al. (1995) IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5:1-17
Weiler, J M; Edens, R E; Bell, C S et al. (1995) Eosinophil granule cationic proteins regulate the classical pathway of complement. Immunology 84:213-9
Edens, R E; Fromm, J R; Fromm, S J et al. (1995) Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III. Biochemistry 34:2400-7
Fromm, J R; Hileman, R E; Caldwell, E E et al. (1995) Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys 323:279-87
Bae, J; Desai, U R; Pervin, A et al. (1994) Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J 301 ( Pt 1):121-9
Bittleman, D B; Maves, K K; Bertolatus, J A et al. (1994) Recurrent infections, pericarditis and renal disease in a patient with total C2 deficiency and decreased NK cell function consistent with acute rheumatic fever and systemic lupus erythematosus. Ann Rheum Dis 53:280-1
Edens, R E; Linhardt, R J; Bell, C S et al. (1994) Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology 27:145-53

Showing the most recent 10 out of 30 publications